323 related articles for article (PubMed ID: 36273157)
1. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
[TBL] [Abstract][Full Text] [Related]
2. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
3. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial subtype
Li Q; Jia Y; Tang B; Yang H; Yang Q; Luo X; Pan Y
Biomarkers; 2023 Dec; 28(7):643-651. PubMed ID: 37886818
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma.
Stromecki M; Tatari N; Morrison LC; Kaur R; Zagozewski J; Palidwor G; Ramaswamy V; Skowron P; Wölfl M; Milde T; Del Bigio MR; Taylor MD; Werbowetski-Ogilvie TE
Mol Oncol; 2018 Apr; 12(4):495-513. PubMed ID: 29377567
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma.
Kameda-Smith MM; Zhu H; Luo EC; Suk Y; Xella A; Yee B; Chokshi C; Xing S; Tan F; Fox RG; Adile AA; Bakhshinyan D; Brown K; Gwynne WD; Subapanditha M; Miletic P; Picard D; Burns I; Moffat J; Paruch K; Fleming A; Hope K; Provias JP; Remke M; Lu Y; Reya T; Venugopal C; Reimand J; Wechsler-Reya RJ; Yeo GW; Singh SK
Nat Commun; 2022 Dec; 13(1):7506. PubMed ID: 36473869
[TBL] [Abstract][Full Text] [Related]
7. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
[TBL] [Abstract][Full Text] [Related]
9. Modeling medulloblastoma in vivo and with human cerebellar organoids.
Ballabio C; Anderle M; Gianesello M; Lago C; Miele E; Cardano M; Aiello G; Piazza S; Caron D; Gianno F; Ciolfi A; Pedace L; Mastronuzzi A; Tartaglia M; Locatelli F; Ferretti E; Giangaspero F; Tiberi L
Nat Commun; 2020 Jan; 11(1):583. PubMed ID: 31996670
[TBL] [Abstract][Full Text] [Related]
10. Effective Inhibition of
Zhao Y; Li T; Tian S; Meng W; Sui Y; Yang J; Wang B; Liang Z; Zhao H; Han Y; Tang Y; Zhang L; Ma J
Cancer Manag Res; 2020; 12():12473-12485. PubMed ID: 33299354
[TBL] [Abstract][Full Text] [Related]
11. OTX2 exhibits cell-context-dependent effects on cellular and molecular properties of human embryonic neural precursors and medulloblastoma cells.
Kaur R; Aiken C; Morrison LC; Rao R; Del Bigio MR; Rampalli S; Werbowetski-Ogilvie T
Dis Model Mech; 2015 Oct; 8(10):1295-309. PubMed ID: 26398939
[TBL] [Abstract][Full Text] [Related]
12. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression.
Chen Y; Ying Y; Ma W; Ma H; Shi L; Gao X; Jia M; Li M; Song X; Kong W; Chen W; Zheng X; Muluh TA; Wang X; Wang M; Shu XS
Cancer Res; 2024 Apr; 84(8):1237-1251. PubMed ID: 38241700
[TBL] [Abstract][Full Text] [Related]
15. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression.
Wolin AR; Vincent MY; Hotz T; Purdy SC; Rosenbaum SR; Hughes CJ; Hsu JY; Oliphant MUJ; Armstrong B; Wessells V; Varella-Garcia M; Galbraith MD; Pierce A; Wang D; Venkataraman S; Danis E; Veo B; Serkova N; Espinosa JM; Gustafson DL; Vibhakar R; Ford HL
Neuro Oncol; 2023 Dec; 25(12):2287-2301. PubMed ID: 37486991
[TBL] [Abstract][Full Text] [Related]
16. Subgroup-Enriched Pathways and Kinase Signatures in Medulloblastoma Patient-Derived Xenografts.
Leskoske KL; Garcia-Mansfield K; Sharma R; Krishnan A; Rusert JM; Mesirov JP; Wechsler-Reya RJ; Pirrotte P
J Proteome Res; 2022 Sep; 21(9):2124-2136. PubMed ID: 35977718
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.
Tsang FH; Law CT; Tang TC; Cheng CL; Chin DW; Tam WV; Wei L; Wong CC; Ng IO; Wong CM
Hepatology; 2019 Jun; 69(6):2502-2517. PubMed ID: 30723918
[TBL] [Abstract][Full Text] [Related]
18. KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma.
Cai H; Liang J; Jiang Y; Wang Z; Li H; Wang W; Wang C; Hou J
J Exp Clin Cancer Res; 2024 Mar; 43(1):69. PubMed ID: 38443991
[TBL] [Abstract][Full Text] [Related]
19. OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma.
Boulay G; Awad ME; Riggi N; Archer TC; Iyer S; Boonseng WE; Rossetti NE; Naigles B; Rengarajan S; Volorio A; Kim JC; Mesirov JP; Tamayo P; Pomeroy SL; Aryee MJ; Rivera MN
Cancer Discov; 2017 Mar; 7(3):288-301. PubMed ID: 28213356
[TBL] [Abstract][Full Text] [Related]
20. Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma.
Deng R; Huang JH; Wang Y; Zhou LH; Wang ZF; Hu BX; Chen YH; Yang D; Mai J; Li ZL; Zhang HL; Huang Y; Peng XD; Feng GK; Zhu XF; Tang J
Mol Cancer; 2020 Aug; 19(1):122. PubMed ID: 32771023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
